{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:12:28Z","timestamp":1790727148109,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejca.2025.116162","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T08:18:34Z","timestamp":1764749914000},"page":"116162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study"],"prefix":"10.1016","volume":"233","author":[{"given":"Paul","family":"Lorigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa Michelle","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Nyakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemie","family":"Rutten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn G.","family":"Feun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Lance","family":"Cowey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israr","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Kuzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"O\u2019Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Sheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip Adam","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja Sue","family":"Bergersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ivind","family":"Foss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen Basmo","family":"Ellingsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bj\u00f8rheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver Edgar","family":"Bechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.116162_bib1","unstructured":"NCCN: NCCN Guidelines Melanoma: Cutaneous Cancer V.3.2023, 2023."},{"key":"10.1016\/j.ejca.2025.116162_bib2","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.annonc.2020.07.004","article-title":"ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee","volume":"31","author":"Keilholz","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116162_bib3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.21.02961","article-title":"Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116162_bib4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116162_bib5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2020.02.021","article-title":"Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019","volume":"130","author":"Ugurel","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.116162_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116162_bib7","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116162_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116162_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116162_bib10","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200239","article-title":"Overall survival and response with nivolumab and relatlimab in advanced melanoma","volume":"2","author":"Long","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ejca.2025.116162_bib11","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ejca.2025.116162_bib12","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Webber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.116162_bib13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines:advancements, challenges and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Sig Transduct Target Ther"},{"issue":"11","key":"10.1016\/j.ejca.2025.116162_bib14","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med Nov"},{"key":"10.1016\/j.ejca.2025.116162_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12929-018-0422-8","article-title":"Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer","volume":"25","author":"Le\u00e3o","year":"2018","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.ejca.2025.116162_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.682492","article-title":"Telomerase as a target for therapeutic cancer vaccines and considerations for optimizing their clinical potential","volume":"12","author":"Ellingsen","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2025.116162_bib17","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2025.116162_bib18","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1038\/onc.2012.441","article-title":"Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells","volume":"32","author":"Liu","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2025.116162_bib19","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/1873-3468.13084","article-title":"Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis","volume":"592","author":"Hannen","year":"2018","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ejca.2025.116162_bib20","doi-asserted-by":"crossref","first-page":"12606","DOI":"10.1073\/pnas.182407599","article-title":"Telomerase contributes to tumorigenesis by a telomere length-independent mechanism","volume":"99","author":"Stewart","year":"2002","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ejca.2025.116162_bib21","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.adengl.2019.02.018","article-title":"Telomerase expression in a series of melanocytic neoplasms","volume":"110","author":"Bustos B","year":"2019","journal-title":"Actas DermoSifiliogr\u00e1ficas (Engl Ed"},{"key":"10.1016\/j.ejca.2025.116162_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju246","article-title":"TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma","volume":"106","author":"Griewank","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2025.116162_bib23","article-title":"The prognostic significance of hTERT overexpression in cancers: a systematic review and meta-analysis","volume":"97","author":"Wang","year":"2018","journal-title":"Med (Baltim)"},{"issue":"2","key":"10.1016\/j.ejca.2025.116162_bib24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jid.2021.07.160","article-title":"Naturally occurring telomerase-specific CD4 T cell immunity in melanoma","volume":"142","author":"Nardin","year":"2022","journal-title":"J Invest Dermatol Feb"},{"key":"10.1016\/j.ejca.2025.116162_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663865","article-title":"Combining a universal telomerase based cancer vaccine with ipilimumab in patients with metastatic melanoma - five-year follow up of a Phase I\/IIa trial","volume":"12","author":"Aamdal","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2025.116162_bib26","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1158\/1078-0432.CCR-23-0416","article-title":"Clinical activity of combined telomerase vaccination and pembrolizumab in advanced melanoma: results from a phase I trial","volume":"29","author":"Ellingsen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.116162_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004345","article-title":"Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials","volume":"10","author":"Ellingsen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.116162_bib28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"33","key":"10.1016\/j.ejca.2025.116162_bib29","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1200\/JCO.24.01125","article-title":"First-line Nivolumab plus relatlimab versus nivolumab plus ipilimumab in advanced melanoma: an indirect treatment comparison using RELATIVITY-047 and CheckMate 067 trial data","volume":"42","author":"Long","year":"2024","journal-title":"J Clin Oncol Nov 20"},{"key":"10.1016\/j.ejca.2025.116162_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.9504","article-title":"Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048","volume":"42","author":"Ascierto","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T17:02:13Z","timestamp":1767718933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925010482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"alternative-id":["S0959804925010482"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116162","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116162","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116162"}}